Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 4/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 2/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.34 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27766191 | 0.88 | NT5E (0.61) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL14591907 | 0.84 | NT5E (0.60) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL11955074 | 0.82 | NT5E (0.57) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL14307070 | 0.82 | NT5E (0.57) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL13197081 | 0.81 | NT5E (0.56) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL1599148 | 0.80 | KDM4E (0.51) | NT5EKDM4ECYP3A4CYP2C19HIF1A | |
| SCHEMBL5558246 | 0.79 | NT5E (1.00) | NT5EKDM4ECYP2C19LMNASLC2A1 | |
| SCHEMBL30492143 | 0.78 | NT5E (0.70) | NT5EKDM4EADRB2LMNAADORA2A | |
| SCHEMBL2709700 | 0.78 | NT5E (0.70) | NT5EKDM4EADRB2LMNAADORA2A | |
| SCHEMBL9724211 | 0.78 | NT5E (0.39) | NT5EKDM4ECYP3A4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448939-B1 | 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-8828997-B2 | 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| EP-2546254-A1 | Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2013-01-16 | — | — | EP | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20120142679-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| US-5112837-A | Inhibitors of thymidylate synthetase enzyme | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-12 | — | — | US | disclosed |
| EP-0318225-A2 | 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | NT5E 2747/4885EGFR 885/4885EPHA2 563/4885 |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | NT5E 2118/4885EGFR 1518/4885EPHA2 4816/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | NT5E 2524/4885EGFR 3925/4885EPHA2 3854/4885 |
| US-20120142679-A1 | NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF | LPXN, LBR, HCLS1 | NT5E 4206/4885EGFR 3561/4885EPHA2 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.